Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-08-17
2002-01-29
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S357000, C514S400000, C514S417000, C514S575000, C546S172000, C546S233000, C548S338100, C548S477000, C562S621000, C562S623000
Reexamination Certificate
active
06342508
ABSTRACT:
BACKGROUND OF THE INVENTION
Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. Of these classes, the gelatinases have been shown to be the MMPs most intimately involved with the growth and spread of tumors. It is known that the level of expression of gelatinase is elevated in malignancies, and that gelatinase can degrade the basement membrane which leads to tumor metastasis. Angiogenesis, required for the growth of solid tumors, has also recently been shown to have a gelatinase component to its pathology. Furthermore, there is evidence to suggest that gelatinase is involved in plaque rupture associated with atherosclerosis. Other conditions mediated by MMPs are restenosis, MMP-mediated osteopenias, inflammatory diseases of the central nervous system, skin aging, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, corneal ulceration, abnormal wound healing, bone disease, proteinmuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, cirrhosis of the liver, glomerular disease of the kidney, premature rupture of fetal membranes, inflammatory bowe disease, periodontal disease, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis
eo-vascularization and corneal graft rejection. For recent reviews, see: (1) Recent Advances in Matrx Metalloproteinase bihibitor Research, R. P. Beckett, A. H. Davidson, A. H. Drummond, P. Huxley and M. Whittaker, Research Focus, Vol. 1, 16-26, (1996), (2) Curr. Opin. Ther. Patents (1994) 4(1): 7-16, (3) Curr. Medicinal Chem. (1995) 2: 743-762, (4) Exp. Opin. Ther. Patents (1995) 5(2): 1087-110, (5) Exp. Opin. Ther. Patents (1995) 5(12): 1287-1196.
TNF-&agr; converting enzyme (TACE) catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. TNF-&agr; is a pro-inflammatory cytokine that is now thought to have a role in rheumatoid arthritis, septic shock, graft rejection, cachexia, anorexia, inflammation, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, insulin resistance and HIV infection in addition to its well documented antitumor properties. For example, research with anti-TNF-&agr; antibodies and transgenic animals has demonstrated that blocking the formation of TNF-&agr; inhibits the progression of arthritis. This observation has recently been extended to humans as well. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. While a variety of MMP and TACE inhibitors have been identified and disclosed in the literate, the vast majority of these molecules are peptidic and peptide-like compounds that one would expect to have bioavailability and pharmacokinetic problems common to such compounds that would limit their clinical effectiveness. Low molecular weight, potent, long acting, orally bioavailable inhibitors of MMPs and/or TACE are therefore highly desirable for the potential chronic treatment of the above mentioned disease states.
Recently, two references have appeared (U.S. Pat. No. 5,455,258 and European Patent Appl. 606,046) that disclose arylsulfonamido-substituted hydroxyamic acids. These documents cover compounds exemplified by CGS 27023A. These are the only non-peptide matrix metalloproteinase inhibitors disclosed to date.
Salah et al., Liebigs Ann. Chem. 195, (1973) discloses some aryl substituted thio and aryl substituted sulfonyl acetohydroxamic acid derivatives of general formula 1. These conpounds were prepared to study the Mannich reaction. Subsequently, they were tested for ther fungicidal activity.
Some sulfone carboxylic acids are disclosed in U.S. Pat. No. 4,933,367. Those compounds were shown to exhibit hypoglycemic activity.
SUMMARY OF THE INVENTION
The present invention relates to novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthtis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.
In accordance with this invention there, is provided a group of compounds of general formula I
wherein:
R
1
is alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R
5
;
alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R
5
;
alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R
5
;
aryl of 6 to 10 carbon atoms, optionally substituted with one or two groups selected independently from R
5
;
cycloalkyl of 3 to 8 carbon atoms, optionally substituted with one or two groups selected independently from R
5
;
saturated or unsaturated mono or bicyclic hetcycle containing one heteroatom selected from O, S or NR
7
, optionally substituted with one or two groups selected independently from R
5
;
or heteroaryl-(CH
2
)
0-6
— wherein the heteroaryl group is 5 to 10 membered monocyclic or bicyclic with one or two heteroatoms selected independently from O, S, and N and may be optionally substituted with one or two groups selected independently from R
5
;
A is —S—, —SO— or SO
2
—;
R
2
and R
3
are independently selected from H;
alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R
5
;
alkenyl of 3 to 18 carbon atoms having from 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R
5
;
alkynyl of 3 to 18 carbon atoms having from 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R
5
;
arylalkyl of 7 to 16 carbon atoms, where aryl is optionally substituted with one or two groups selected independently from R
5
;
biphenylalkyl of 13 to 18 carbon atoms, where biphenyl is optionally substituted with one or two groups selected independently from R
5
;
arylalkenyl of 8 to 16 carbon atoms, where aryl is optionally substituted with one or two groups selected independently from R
5
;
cycloalkylalkyl or bicycloalkylalkyl of 4 to 12 carbon atoms, optionally substituted with one or two groups selected independently from R
5
;
saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR
7
, optionally substituted with one or two groups selected independently from R
5
;
R
8
R
9
N—C
1
-C
6
-alkoxyaryl-C
1
-C
6
-alkyl where R
8
and R
9
are independently selected from C
1
-C
6
alkyl or R
8
and R
9
together with the interposed nitrogen forms a 5-7 membered saturated heterocyclic ring optionally containing an oxygen atom, wherein the aryl group is phenyl or naphthyl;
or heteroaryl-(CH
2
)
0-6
-wherein the heteroaryl group is 5 to 10 membered monocyclic or bicyclic with one or two heteroatoms selected independently from O, S, and N and may be optionally substituted with one or two groups selected independently from R
5
;
R
4
is hydrogen,
alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R
5
;
alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R
5
;
alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R
5
;
phenyl or naphthyl optionally substituted with one or two groups selected independently from R
5
;
C
3
to C
8
cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected i
Cole Derek Cecil
Davis Jamie Marie
Grosu George Theodore
Venkatesan Aranapakam Mudumbai
American Cyanamid Company
Hogan Jr. John W.
Raymond Richard L.
LandOfFree
N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2845928